<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101060</url>
  </required_header>
  <id_info>
    <org_study_id>O0667-R</org_study_id>
    <nct_id>NCT02101060</nct_id>
  </id_info>
  <brief_title>Strength Training and Endurance Exercise for LIFE</brief_title>
  <acronym>STEEL</acronym>
  <official_title>Effect of Exercise Training on Inflammation and Function in HIV Infected Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research is needed to determine safe and effective exercise rehabilitation programs to&#xD;
      prevent and improve physical disability in older adults living with HIV. This problem is of&#xD;
      great importance to the VA. The majority of the 25 thousand HIV-infected veterans are over 50&#xD;
      years of age (64%). The combined effect of aging and inflammation increase the risk for&#xD;
      physical disability in older HIV-infected veterans. This translational exercise training&#xD;
      trial will examine the cardiac and skeletal muscle effects of combined aerobic exercise and&#xD;
      resistance training to attenuate the functional declines of aging with HIV by reducing the&#xD;
      deleterious consequences of chronic inflammation. Findings will guide future rehabilitation&#xD;
      research on cardiac remodeling and inflammation of skeletal muscle. The proposed research&#xD;
      will advance the goal to develop effective rehabilitation strategies that improve the health&#xD;
      of older HIV-infected veterans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine the effect of exercise training on the central&#xD;
      (cardiovascular) and peripheral (muscular) impairments underlying poor physical function by&#xD;
      comparing older HIV-infected veterans randomized to combine aerobic and resistance exercise&#xD;
      training versus usual care. The study hypothesis is that a progressive aerobic and resistance&#xD;
      rehabilitation program will increase aerobic capacity and muscle strength, which will be&#xD;
      mediated by improved diastolic function, increased muscle mass, and decreased systemic&#xD;
      inflammation. To test this hypothesis, investigators will conduct a randomized 16-week trial&#xD;
      of progressive aerobic and resistance training versus usual care control in 40 sedentary&#xD;
      older (50+ years) HIV-infected veterans. The study will determine the effects of exercise&#xD;
      training on aerobic capacity and diastolic function, and their relationship to changes in&#xD;
      biomarkers of systemic inflammation and cardiac fibrosis (AIM 1). The study will also&#xD;
      determine the effect of exercise training on strength and muscle mass, and their relationship&#xD;
      to changes in biomarkers of systemic inflammation (AIM 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2014</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aerobic Capacity</measure>
    <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
    <description>VO2 peak will be used as the primary measure of aerobic capacity. Subjects will be asked to exercise to voluntary exhaustion during a treadmill test using a modified Bruce protocol.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Function</measure>
    <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
    <description>Exercise stress two-dimensional transthoracic echocardiography with tissue Doppler imaging (stress-echo) will be used to collect data on diastolic function. Reporting on ejection fraction.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Systemic Inflammation</measure>
    <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
    <description>Changes in plasma levels of biomarkers of chronic inflammation will be calculated pre/post intervention, and will be tested for association with changes in primary outcomes as well as between group differences. Presenting IL-18 values (log converted for analysis).&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16-week progressive aerobic and resistance exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>16-week progressive aerobic and resistance exercise training</description>
    <arm_group_label>exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected veterans adult 50 years of age and older under medical care for HIV&#xD;
&#xD;
          -  Antiretroviral Therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with comorbid conditions that could have a potential impact on their ability&#xD;
             to perform exercise testing and training will be excluded according to the American&#xD;
             College of Sports Medicine&#xD;
&#xD;
          -  Only sedentary adults will be eligible. Individuals that participate in regular&#xD;
             structured aerobic exercise or resistance training in the prior 6-months will be&#xD;
             excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris Ann K Oursler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salem VA Medical Center, Salem, VA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center, Salem, VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Briggs BC, Ryan AS, Sorkin JD, Oursler KK. Feasibility and effects of high-intensity interval training in older adults living with HIV. J Sports Sci. 2021 Feb;39(3):304-311. doi: 10.1080/02640414.2020.1818949. Epub 2020 Sep 23.</citation>
    <PMID>32962523</PMID>
  </results_reference>
  <results_reference>
    <citation>Oursler KK, O'Boyle HM, Briggs BC, Sorkin JD, Jarmukli N, Katzel LI, Freiberg MS, Ryan AS. Association of Diastolic Dysfunction with Reduced Cardiorespiratory Fitness in Adults Living with HIV. AIDS Patient Care STDS. 2019 Dec;33(12):493-499. doi: 10.1089/apc.2019.0149.</citation>
    <PMID>31821043</PMID>
  </results_reference>
  <results_reference>
    <citation>Oursler KK, Iranmanesh A, Jain C, Birkett KL, Briggs BC, Garner DC, Sorkin JD, Ryan AS. Short Communication: Low Muscle Mass Is Associated with Osteoporosis in Older Adults Living with HIV. AIDS Res Hum Retroviruses. 2020 Apr;36(4):300-302. doi: 10.1089/AID.2019.0207. Epub 2019 Dec 23.</citation>
    <PMID>31762303</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan AS, Roy A, Oursler KK. Gait and Balance Biomechanics in Older Adults With and Without Human Immunodeficiency Virus. AIDS Res Hum Retroviruses. 2019 Nov/Dec;35(11-12):1089-1094. doi: 10.1089/AID.2019.0102.</citation>
    <PMID>31547668</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <results_first_submitted>February 18, 2021</results_first_submitted>
  <results_first_submitted_qc>April 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>aging</keyword>
  <keyword>aerobic capacity</keyword>
  <keyword>cardiac function</keyword>
  <keyword>inflammation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02101060/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exercise</title>
          <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>usual care controls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exercise</title>
          <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>usual care controls</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.03" spread="6.1"/>
                    <measurement group_id="B2" value="61.17" spread="7.4"/>
                    <measurement group_id="B3" value="61.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aerobic Capacity</title>
        <description>VO2 peak will be used as the primary measure of aerobic capacity. Subjects will be asked to exercise to voluntary exhaustion during a treadmill test using a modified Bruce protocol.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
        <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
        <population>We have incomplete data on completers in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>usual care controls</description>
          </group>
        </group_list>
        <measure>
          <title>Aerobic Capacity</title>
          <description>VO2 peak will be used as the primary measure of aerobic capacity. Subjects will be asked to exercise to voluntary exhaustion during a treadmill test using a modified Bruce protocol.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
          <population>We have incomplete data on completers in the control group.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.04"/>
                    <measurement group_id="O2" value="0.02" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Function</title>
        <description>Exercise stress two-dimensional transthoracic echocardiography with tissue Doppler imaging (stress-echo) will be used to collect data on diastolic function. Reporting on ejection fraction.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
        <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
        <population>We have incomplete data on completers in these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>usual care controls</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Function</title>
          <description>Exercise stress two-dimensional transthoracic echocardiography with tissue Doppler imaging (stress-echo) will be used to collect data on diastolic function. Reporting on ejection fraction.&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
          <population>We have incomplete data on completers in these groups.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.9"/>
                    <measurement group_id="O2" value="0.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Systemic Inflammation</title>
        <description>Changes in plasma levels of biomarkers of chronic inflammation will be calculated pre/post intervention, and will be tested for association with changes in primary outcomes as well as between group differences. Presenting IL-18 values (log converted for analysis).&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
        <time_frame>at baseline and at 16 weeks (before and after the intervention phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>usual care controls</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Systemic Inflammation</title>
          <description>Changes in plasma levels of biomarkers of chronic inflammation will be calculated pre/post intervention, and will be tested for association with changes in primary outcomes as well as between group differences. Presenting IL-18 values (log converted for analysis).&#xD;
In this Outcome, a mean difference between baseline to 16 weeks is reported (value at 16 weeks minus value at baseline).</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected from time of enrollment to completion of study. For intervention group, duration of study is approximately 30 weeks. For control group, duration of study is approximately 50 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exercise</title>
          <description>16-week progressive aerobic and resistance exercise training&#xD;
exercise: 16-week progressive aerobic and resistance exercise training</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>usual care controls</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>reoccurrence of pre-existing Supraventricular tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <description>In delayed entry exercise of control group</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>In delayed entry exercise of control group</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Exclusion criteria may limit the generalizability of findings. While AIDS-related conditions are an exclusion criteria, the period is limited to the prior 6 months. In order to minimize confounding by ART medication, we require participants to be on the same regimen for at least 3 months prior to enrollment. Therefore, we have included a control group without exercise and assume that the risk of confounding from ART and other medications will be equally distributed across groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Krisann Oursler</name_or_title>
      <organization>Salem VA Medical Center</organization>
      <phone>540-982-2463 ext 4981</phone>
      <email>krisann.oursler@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

